NASDAQ:AKUS Akouos - AKUS Stock Forecast, Price & News Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Akouos, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Add Compare Share Share Today's Range$13.29▼$13.2950-Day Range$13.29▼$13.2952-Week Range$2.32▼$13.60Volume440 shsAverage Volume344,411 shsMarket Capitalization$490.88 millionP/E RatioN/ADividend YieldN/APrice Target$12.50 ProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media About Akouos (NASDAQ:AKUS) StockAkouos, Inc., a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals. The company's precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate is AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. The company is also developing AK-CLRN1 for the auditory manifestations of Usher syndrome 3A, or USH3A; and AK-antiVEGF for vestibular schwannoma. In addition, its precision genetic medicine platform addresses hearing loss related to genes needed for supporting cell function. The company was incorporated in 2016 and is based in Boston, Massachusetts.Read More Receive AKUS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Akouos and its competitors with MarketBeat's FREE daily newsletter. Email Address AKUS Stock News HeadlinesDecember 1, 2022 | finance.yahoo.comLilly Completes Acquisition of Akouos Expanding Efforts to Help People with Genetic DiseasesNovember 14, 2022 | finance.yahoo.comAkouos Reports Third Quarter 2022 Financial Results and Provides Business HighlightsMarch 27, 2023 | Behind the Markets (Ad)Buy THIS stock before Taiwan is attacked... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.October 19, 2022 | seekingalpha.comAkouos stock soars 87% as Lilly nabs hearing loss gene therapy developer - Seeking AlphaOctober 18, 2022 | businesswire.comAKUS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Akouos, Inc. Is Fair to Shareholders - Business WireOctober 18, 2022 | benzinga.comCrude Oil Drops Over 2%; Akouos Shares Spike Higher - Akouos (NASDAQ:AKUS), ADS-TEC Energy (NASDAQ:ADSE) - BenzingaOctober 18, 2022 | nasdaq.comEli Lilly to buy genetic medicine developer Akouos for $487 million - NasdaqOctober 18, 2022 | marketwatch.comEli Lilly to Buy Akouos for Up to $610 Million >LLY AKUS - MarketWatchMarch 27, 2023 | Behind the Markets (Ad)Buy THIS stock before Taiwan is attacked... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.October 18, 2022 | marketwatch.comAkouos Shares Soar on Takeover by Eli Lilly >AKUS - MarketWatchOctober 18, 2022 | marketwatch.comEli Lilly to acquire Akouos for up to about $610 million and develop gene therapies for hearing loss - MarketWatchOctober 18, 2022 | nasdaq.comEli Lilly To Buy Akouos For Up To $610 Mln - NasdaqOctober 18, 2022 | streetinsider.comEli Lilly & Co. (LLY) Acquires Akouos (AKUS) for $610M - StreetInsider.comOctober 10, 2022 | nasdaq.comAkouos, Inc. (AKUS) Upgraded to Strong Buy: Here's Why - NasdaqOctober 10, 2022 | finance.yahoo.comAkouos, Inc. (AKUS) Upgraded to Strong Buy: Here's WhySeptember 29, 2022 | seekingalpha.comAKUS stock rated Bullish at William Blair on gene therapy for hearing loss (NASDAQ:AKUS) - Seeking AlphaSeptember 27, 2022 | finance.yahoo.comArthur Tzianabos, Ph.D., June Lee, MD FACCP, and Joseph Loscalzo, MD, Ph.D. Join 5AM Ventures - Yahoo FinanceSeptember 14, 2022 | uk.investing.comWhy Comera Life Sciences Shares Jumped 101%; Here Are 74 Biggest Movers From Yesterday By Benzinga - Investing.com UKSeptember 14, 2022 | finance.yahoo.comAlcohol Justice to Participate at Alcohol Policy-19 Evidence to Action: Building a Framework for Change - Yahoo FinanceSeptember 13, 2022 | finance.yahoo.comFDA Clears Akouos' Gene Therapy Trial For Genetic Form Of Hearing LossSeptember 13, 2022 | finance.yahoo.comAkouos Receives FDA Clearance of its IND Application for AK-OTOF, a Gene Therapy Intended for the Treatment of OTOF-mediated Hearing LossSeptember 13, 2022 | markets.businessinsider.comAkouos Says FDA Clears IND Application For AK-OTOF For OTOF-mediated Hearing LossSeptember 13, 2022 | seekingalpha.comAkouos stock rises 11% on FDA clearance to start gene therapy trial for hearing loss - Seeking AlphaSeptember 9, 2022 | streetinsider.comForm SC 13G/A Akouos, Inc. Filed by: FEDERATED HERMES, INC. - StreetInsider.comAugust 18, 2022 | nasdaq.comAkouos, Inc. (AKUS) Upgraded to Buy: Here's Why - NasdaqAugust 18, 2022 | finance.yahoo.comAkouos, Inc. (AKUS) Upgraded to Buy: Here's WhyAugust 16, 2022 | benzinga.comThis Financial Services Stock Surged Around 116%; Here Are 86 Biggest Movers From Yesterday - BenzingaSee More Headlines Receive AKUS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Akouos and its competitors with MarketBeat's FREE daily newsletter. Email Address AKUS Company Calendar Last Earnings11/12/2021Today3/26/2023Next Earnings (Estimated)4/04/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AKUS CUSIPN/A CIK1722271 Webwww.akouos.com Phone857-410-1818FaxN/AEmployees103Year FoundedN/APrice Target and Rating Average Stock Price Forecast$12.50 High Stock Price Forecast$13.00 Low Stock Price Forecast$12.00 Forecasted Upside/Downside-5.9%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($2.62) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-86,670,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-45.09% Return on Assets-36.86% Debt Debt-to-Equity RatioN/A Current Ratio17.30 Quick Ratio17.30 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.90 per share Price / Book2.71Miscellaneous Outstanding Shares36,936,000Free Float35,163,000Market Cap$490.88 million OptionableNot Optionable Beta-0.55 Key ExecutivesDr. Emmanuel Simons M.B.A. (Age 39)Ph.D., Co- Founder, Pres, CEO & Director Comp: $790.72kDr. Michael John McKenna M.D. (Age 65)Co-Founder, Chief Medical Officer & Member of Scientific Advisory Board Comp: $539.35kMs. Jennifer Anne Wellman M.S. (Age 44)Chief Operating Officer Comp: $568.67kDr. Luk H. Vandenberghe M.D.Ph.D., Founder & Member of Scientific Advisory BoardMr. William F. Sewell Ph.D.Founder & Member of Scientific Advisory BoardMr. Richard Smith M.D.Founder & Member of Scientific Advisory BoardMs. Sachiyo Minegishi (Age 44)CFO, Treasurer, Assistant Sec. & Principal Accounting Officer Ms. Stacy PriceChief Technical OfficerDr. Aaron Tward M.D.Ph.D., Chief Scientific OfficerDr. Karoline K. ShairSr. VP, Gen. Counsel, Chief Legal Officer & Corp. Sec.More ExecutivesKey CompetitorsArbutus BiopharmaNASDAQ:ABUSJanux TherapeuticsNASDAQ:JANXEvolusNASDAQ:EOLSLyell ImmunopharmaNASDAQ:LYELHarrow HealthNASDAQ:HROWView All CompetitorsInsiders & InstitutionsCredit Suisse AGBought 13,668 shares on 2/13/2023Ownership: 0.037%Simplex Trading LLCSold 100 shares on 2/2/2023Ownership: 0.000%Acquisition Corp KearnyBought 29,992,668 shares on 11/30/2022Total: $374.91 M ($12.50/share)View All Insider TransactionsView All Institutional Transactions AKUS Stock - Frequently Asked Questions Should I buy or sell Akouos stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Akouos in the last twelve months. There are currently 3 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" AKUS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AKUS, but not buy additional shares or sell existing shares. View AKUS analyst ratings or view top-rated stocks. What is Akouos' stock price forecast for 2023? 3 brokers have issued 12-month target prices for Akouos' stock. Their AKUS share price forecasts range from $12.00 to $13.00. On average, they anticipate the company's share price to reach $12.50 in the next year. This suggests that the stock has a possible downside of 5.9%. View analysts price targets for AKUS or view top-rated stocks among Wall Street analysts. When is Akouos' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 4th 2023. View our AKUS earnings forecast. How were Akouos' earnings last quarter? Akouos, Inc. (NASDAQ:AKUS) released its quarterly earnings results on Friday, November, 12th. The company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.63) by $0.04. What other stocks do shareholders of Akouos own? Based on aggregate information from My MarketBeat watchlists, some companies that other Akouos investors own include NVIDIA (NVDA), Honeywell International (HON), QUALCOMM (QCOM), Raytheon Technologies (RTX), CVS Health (CVS), Johnson & Johnson (JNJ), Cisco Systems (CSCO), Home Depot (HD), Pfizer (PFE) and Procter & Gamble (PG). When did Akouos IPO? (AKUS) raised $124 million in an initial public offering (IPO) on Friday, June 26th 2020. The company issued 8,300,000 shares at a price of $14.00-$16.00 per share. BofA Securities, Cowen and Piper Sandler acted as the underwriters for the IPO and BTIG was co-manager. What is Akouos' stock symbol? Akouos trades on the NASDAQ under the ticker symbol "AKUS." Who are Akouos' major shareholders? Akouos' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Credit Suisse AG (0.04%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). View institutional ownership trends. What is Akouos' stock price today? One share of AKUS stock can currently be purchased for approximately $13.29. How much money does Akouos make? Akouos (NASDAQ:AKUS) has a market capitalization of $490.88 million. The company earns $-86,670,000.00 in net income (profit) each year or ($2.62) on an earnings per share basis. How many employees does Akouos have? The company employs 103 workers across the globe. How can I contact Akouos? Akouos' mailing address is 645 SUMMER STREET SUITE 200, BOSTON MA, 02210. The official website for the company is www.akouos.com. The company can be reached via phone at 857-410-1818 or via email at turiano@sternir.com. This page (NASDAQ:AKUS) was last updated on 3/27/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.